Biology Department, Center for Computational and Integrative Biology, Rutgers University, Camden, NJ, United States.
Department of Basic Sciences, Parker University, Dallas, TX, United States.
Front Endocrinol (Lausanne). 2023 Aug 28;14:1210540. doi: 10.3389/fendo.2023.1210540. eCollection 2023.
We review the evidence regarding the nongenomic (or non-canonical) actions of thyroid hormones (thyronines) and their derivatives (including thyronamines and thyroacetic acids) in the adult brain. The paper seeks to evaluate these compounds for consideration as candidate neurotransmitters. Neurotransmitters are defined by their (a) presence in the neural tissue, (b) release from neural tissue or cell, (c) binding to high-affinity and saturable recognition sites, (d) triggering of a specific effector mechanism and (e) inactivation mechanism. Thyronines and thyronamines are concentrated in brain tissue and show distinctive patterns of distribution within the brain. Nerve terminals accumulate a large amount of thyroid hormones in mature brain, suggesting a synaptic function. However, surprisingly little is known about the potential release of thyroid hormones at synapses. There are specific binding sites for thyroid hormones in nerve-terminal fractions (synaptosomes). A notable cell-membrane binding site for thyroid hormones is integrin αvβ3. Furthermore, thyronines bind specifically to other defined neurotransmitter receptors, including GABAergic, catecholaminergic, glutamatergic, serotonergic and cholinergic systems. Here, the thyronines tend to bind to sites other than the primary sites and have allosteric effects. Thyronamines also bind to specific membrane receptors, including the trace amine associated receptors (TAARs), especially TAAR1. The thyronines and thyronamines activate specific effector mechanisms that are short in latency and often occur in subcellular fractions lacking nuclei, suggesting nongenomic actions. Some of the effector mechanisms for thyronines include effects on protein phosphorylation, Na/K ATPase, and behavioral measures such as sleep regulation and measures of memory retention. Thyronamines promptly regulate body temperature. Lastly, there are numerous inactivation mechanisms for the hormones, including decarboxylation, deiodination, oxidative deamination, glucuronidation, sulfation and acetylation. Therefore, at the current state of the research field, thyroid hormones and their derivatives satisfy most, but not all, of the criteria for definition as neurotransmitters.
我们回顾了甲状腺激素(甲状腺素)及其衍生物(包括甲状腺胺和甲状腺乙酸)在成年大脑中的非基因组(或非典型)作用的证据。本文旨在评估这些化合物作为候选神经递质的可能性。神经递质的定义为:(a)存在于神经组织中,(b)从神经组织或细胞中释放,(c)与高亲和力和饱和识别位点结合,(d)触发特定效应机制,(e)失活机制。甲状腺素和甲状腺胺集中在脑组织中,并在大脑内呈现出独特的分布模式。神经末梢在成熟的大脑中积累了大量的甲状腺激素,提示其具有突触功能。然而,关于甲状腺激素在突触处潜在释放的知识却知之甚少。神经末梢部分(突触体)存在甲状腺激素的特异性结合位点。整合素αvβ3 是甲状腺激素的一个显著的细胞膜结合位点。此外,甲状腺素还特异性地结合到其他已定义的神经递质受体,包括 GABA 能、儿茶酚胺能、谷氨酸能、5-羟色胺能和胆碱能系统。在这些受体中,甲状腺素倾向于与主要结合位点以外的位点结合,并具有变构效应。甲状腺胺也与特定的膜受体结合,包括微量胺相关受体(TAARs),特别是 TAAR1。甲状腺素和甲状腺胺激活特定的效应机制,这些机制潜伏期短,通常发生在缺乏细胞核的亚细胞部分,提示其具有非基因组作用。甲状腺素的一些效应机制包括对蛋白质磷酸化、Na/K ATP 酶的影响,以及睡眠调节和记忆保留等行为测量。甲状腺胺能迅速调节体温。最后,这些激素有许多失活机制,包括脱羧、脱碘、氧化脱氨、糖基化、硫酸化和乙酰化。因此,在当前的研究领域中,甲状腺激素及其衍生物满足作为神经递质的大部分定义标准,但并非全部。